By Newsgd.com

“It’s more than better treatment, but also financial relief,” Mr. Tian said at C-MER(Zhuhai) Dennis Lam Eye Hospital in Zhuhai on March 27, who received the first injection of Brolucizumab, the first imported medicine introduced into the city under the “Hong Kong and Macao Medicine and Equipment Connect”.

Brolucizumab is used to treat wet age-related macular degeneration, a persistent eye disease causing loss of the ability to see. It is also the first eye medicine introduced in mainland cities in the Greater Bay Area (GBA), since the launch of the “Hong Kong and Macau Medicine and Equipment Connect” in late 2020.

The program allows designated hospitals in mainland GBA cities to use Hong Kong and Macao-approved drugs and medical devices without any prior certification from the National Medical Products Administration.

According to Mr. Tian, ​​he had to receive 5 or 6 injections a year in the past. With this new drug, however, the annual number of injections can be reduced to 3 or 4.

“Compared to existing therapy, brolucizumab’s ability to absorb and control intraretinal fluid allows for a longer dosing interval,” said hospital president Dennis Lam.